Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment

• Published in: Antimicrobial agents and chemotherapy Vol. 60; no. 9; pp. 5135 - 5140
• Main Authors: Custodio, Joseph M., Fordyce, Marshall, Garner, William, Vimal, Mona, Ling, Kah Hiing J., Kearney, Brian P., Ramanathan, Srinivasan
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.09.2016
• Subjects: Adenine; Adenine - analogs & derivatives; Adenine - blood; Adenine - pharmacokinetics; Aged; Anti-HIV Agents; Anti-HIV Agents - blood; Anti-HIV Agents - pharmacokinetics; Area Under Curve; Case-Control Studies; Clinical Therapeutics; Female; Glomerular Filtration Rate; HIV Infections; Human immunodeficiency virus; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Renal Insufficiency, Chronic - blood; Renal Insufficiency, Chronic - physiopathology

Tenofovir alafenamide (TAF) is an oral prodrug of tenofovir (TFV) that has greater stability in plasma than TFV disoproxil fumarate (TDF) and circulates as intact TAF, resulting in the direct and higher lymphatic loading of and exposure to TFV diphosphate, the active moiety. Unlike TFV, TAF is minim...